DUODOPA is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease with severe motor fluctuations and hyperkinesia or dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.1
As part of AbbVie’s commitment to recognising and managing complex/advanced Parkinson’s disease, we have developed a series of downloadable resources for healthcare professionals. These provide guidance on the role device-aided therapy plays in the management of Parkinson’s disease and where it fits in the patient treatment pathway.
Additional insights on the management of complex/advanced Parkinson's disease can be found in the on-demand AbbVie promotional sponsored symposium from the Parkinson's Academy webinar in May 2021.
Downloadable materials for HCPs
Providing guidance on when and how to introduce conversations with patients about advanced care planning as their disease progresses.
How considering motor, non-motor, and functional indicators of disease progression can help identify people with complex/advanced Parkinson’s and may support timely referral for device-aided therapies.
UK-DUOD-210201. Date of preparation: December 2021.
You are now leaving the AbbVie Pro Portal and being re-directed to an external website which is not under the control of AbbVie. AbbVie is not responsible for content of any such site or any further links from such site.
Reporting of side effects (patients and public in the UK)
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk.
By reporting side effects you can help provide more information on the safety of this medicine.
For medicines with black triangle: ▼ means the medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See https://yellowcard.mhra.gov.uk for how to report side effects.